Part I: Interactive case: Adverse effects associated with antipsychotic therapy

2021 ◽  
Vol 4 (12) ◽  
pp. 1618-1623
Author(s):  
Kristen N. Gardner
Keyword(s):  
Adverse Effects ◽  
Antipsychotic Therapy

scholarly journals Pharmacogenetics of antipsychotic therapy: pivotal research issues and the prospects for clinical implementation

2006 ◽  
Vol 8 (1) ◽  
pp. 85-94 ◽  
Keyword(s):  
Adverse Effects ◽  
Genetic Factors ◽  
Association Studies ◽  
Environment Interaction ◽  
Clinical Implementation ◽  
Antipsychotic Therapy ◽  
Research Issues ◽  
Recent Developments ◽  
And Gender ◽  
The Individual

The core hypothesis underlying pharmacogenetics is that genetic factors play a significant role in the well-recognized differences between individuals in response to medication and susceptibility to adverse effects. If these genetic factors can be identified and understood, they may serve as predictors to guide clinicians in tailoring medication to the individual patient. Recent developments in the field of antipsychotic drug treatment suggest that pharmacogenetics could play an important role, permitting the use of first-generation antipsychotics (FGAs) for patients in whom the use of second-generation antipsychotics (SGAs) is limited by efficacy considerations or adverse effects. In this paper, key issues that need to be taken into consideration in designing and interpreting pharmacogenetic studies of antipsychotic drugs are discussed against the background of data emanating from studies on the genetics of tardive dyskinesia (TD), an important adverse effect of FGAs. The issues considered include the advantages and potential pitfalls of case-control association studies of pharmacogenetic traits, the role of demographic factors such as age and gender, additive effects of genes, and gene-gene and gene-environment interaction. The prospects for implementation of pharmacogenetic testing in the clinic are considered in the context of a preliminary model that has been tested for prediction of susceptibility to TD.

scholarly journals Adverse ocular effects of neuroleptic therapy: semiotics, pathogenesis and treatment

2022 ◽  
Vol 14 (4) ◽  
pp. 172-178
Author(s):  
A. A. Panov ◽  
A. A. Petukhova ◽  
Ya. V. Malygin ◽  
B. D. Tsygankov ◽  
M. A. Kazanfarova
Keyword(s):  
Side Effects ◽  
Adverse Effects ◽  
Clinical Manifestations ◽  
Corneal Edema ◽  
Acute Angle ◽  
Angle Closure ◽  
Antipsychotic Therapy ◽  
Ocular Side ◽  
Acute Angle Closure ◽  
Therapy Modification

Antipsychotics are widely used in psychiatric practice for treating schizophrenia, bipolar disorder, and other diseases, including those treated off-label. They manifest many adverse effects, including ophthalmic ones. Some of these effects, such as persistent mydriasis, cycloplegia, extraocular muscle dystonia, and visual hypersensitivity attacks are reversible, since they disappear after dose reduction or drug withdrawal. Yet other side effects, such as cataracts, corneal edema, acute angle closure glaucoma and retinopathy are threatening for sight and may lead to permanent visual acuity decline and even blindness. The review provides data on the incidence of ocular side effects (both typical and atypical) of multiple antipsychotics, their clinical manifestations, pathogenesis and treatment. Eye examination is recommended for patients taking antipsychotics in the early periods of treatment and then twice a year. The psychiatrists need to know about the adverse effects of individual drugs whilst the ophthalmologists should be aware of their semiotics, pathogenesis and treatment, since timely diagnosis and treatment of pathological changes, together with antipsychotic therapy modification, prevent the development of severe and irreversible visual impairment in the majority of cases.

scholarly journals The use of concurrent long-acting injectable antipsychotic therapy with paliperidone palmitate and aripiprazole monohydrate in a patient with schizophrenia

2021 ◽  
Vol 11 (5) ◽  
pp. 305-310
Author(s):  
Christopher Evernden ◽  
Irene Giang ◽  
Mariah Anderson
Keyword(s):  
Adverse Effects ◽  
Single Agent ◽  
Paliperidone Palmitate ◽  
Symptom Reduction ◽  
Patient Case ◽  
Antipsychotic Therapy ◽  
Antipsychotic Medications ◽  
Oral Medications ◽  
History Of ◽  
Long Acting

Abstract International schizophrenia guidelines endorse seeking the patient's preference for guiding antipsychotic therapy. There exists a small niche of patients who prefer, or are required to use, long-acting injectable antipsychotic medications due to the adherence benefit. However, they may not be able to achieve adequate symptom reduction prior to experiencing treatment-limiting adverse effects from a single agent. Here, we present a patient case prescribed concurrent long-acting injectable antipsychotic therapy with paliperidone palmitate and aripiprazole monohydrate due to patient preference in the setting of a history of nonadherence to oral medications, treatment-limiting adverse effects to long-acting injectable paliperidone, and failure to achieve adequate symptom reduction with long-acting injectable aripiprazole monotherapy.

Emerging pharmacological therapies in schizophrenia: what’s new, what’s different, what’s next?

CNS Spectrums ◽  
2016 ◽  
Vol 21 (S1) ◽  
pp. 1-12 ◽  
Author(s):  
Leslie Citrome
Keyword(s):  
Adverse Effects ◽  
Tardive Dyskinesia ◽  
Maintenance Treatment ◽  
Clinical Development ◽  
Phase Iii ◽  
Time Interval ◽  
Antipsychotic Therapy ◽  
Partial Agonists ◽  
Long Acting ◽  
Novel Antipsychotic

There are several new and emerging medication interventions for both the acute and maintenance treatment phases of schizophrenia. Recently approved are 2 new dopamine receptor partial agonists, brexpiprazole and cariprazine, as well as 2 new long-acting injectable antipsychotic formulations, aripiprazole lauroxil and 3-month paliperidone palmitate. Although differences in efficacy compared to other available choices are not expected, the new oral options offer different tolerability profiles that may be attractive for individual patients who have had difficulties with older medications. The new long-acting injectable options provide additional flexibility in terms of increasing the time interval between injections. In Phase III of clinical development is a novel antipsychotic, lumateperone (ITI-007), that appears to have little in the way of significant adverse effects. Deutetrabenazine and valbenazine are agents in Phase III for the treatment of tardive dyskinesia, a condition that can be found among persons receiving chronic antipsychotic therapy. On the horizon are additional injectable formulations of familiar antipsychotics, aripiprazole and risperidone, that may be more convenient than what is presently available.

The Influence of Specimen Thickness in Quantitative Electron Energy Loss Spectroscopy

1980 ◽  
Vol 38 ◽  
pp. 112-113
Author(s):  
Nestor J. Zaluzec
Keyword(s):  
Quantitative Analysis ◽  
Adverse Effects ◽  
Energy Loss ◽  
Electron Energy ◽  
Electron Energy Loss Spectroscopy ◽  
Materials Science ◽  
Light Element ◽  
Specimen Thickness ◽  
Element Analysis ◽  
Electron Energy Loss

The application of electron energy loss spectroscopy (EELS) to light element analysis is rapidly becoming an important aspect of the microcharacterization of solids in materials science, however relatively stringent requirements exist on the specimen thickness under which one can obtain EELS data due to the adverse effects of multiple inelastic scattering.1,2 This study was initiated to determine the limitations on quantitative analysis of EELS data due to specimen thickness.

The Adverse Effects of a Language Disorder

2002 ◽  
Vol 3 (2) ◽  
pp. 12-17
Author(s):  
Sandra A. Karas
Keyword(s):  
Adverse Effects ◽  
Language Disorder

Sepsis Protocol Helps Minimize Adverse Effects of High BMI

2007 ◽  
Vol 40 (14) ◽  
pp. 38
Author(s):  
MARY ELLEN SCHNEIDER
Keyword(s):  
Adverse Effects ◽  
High Bmi

Adverse effects of shift work in healthcare professionals

2003 ◽  
Vol 3 (2) ◽  
pp. 293-309
Author(s):  
S PATEL ◽  
E OMALLEY
Keyword(s):  
Adverse Effects ◽  
Shift Work ◽  
Healthcare Professionals

How often do heart failure patients perceive adverse effects of their medication and how do they deal with them?

2008 ◽  
Vol 7 ◽  
pp. 57-57
Author(s):  
R DESMEDT ◽  
T JAARSMA ◽  
F HAAIJERRUSKAMP
Keyword(s):  
Heart Failure ◽  
Adverse Effects ◽  
Heart Failure Patients

Abhängigkeitspotenzial und andere Risiken von Opioidanalgetika im Alter

2017 ◽  
Vol 63 (2) ◽  
pp. 99-114 ◽  
Author(s):  
Dirk K. Wolter
Keyword(s):  
Adverse Effects ◽  
Psychische Störungen ◽  
Opioid Analgesics ◽  
Alte Menschen ◽  
Dsm 5 ◽  
Icd 10

Zusammenfassung. Zielsetzung: Übersicht über Suchtpotenzial und andere Risiken von Opioidanalgetika im höheren Lebensalter. Methodik: Narrativ review. Literaturrecherche in PubMed (Suchbegriffe: opioid analgesics UND abuse; opioid analgesics UND dependence; opioid analgesics UND addiction; opioid analgesics UND adverse effects; jeweils UND elderly) sowie aktuellen einschlägigen Standardwerken; Auswahl nach altersmedizinischer Relevanz und Aktualität. Ergebnisse: Die Verordnung von Opioidanalgetika (OA) hat in den letzten 25 Jahren massiv zugenommen, die weitaus meisten Verordnungen entfallen auf alte Menschen und Menschen mit chronischen Nicht-Tumorschmerzen (CNTS). Die diagnostischen Kriterien für die Opiatabhängigkeit in ICD-10 und DSM-5 sind für die OA-Behandlung von CNTS ungeeignet. Bei langfristiger OA-Behandlung bei CNTS kann eine spezifische Form von Abhängigkeit entstehen, die nicht mit der illegalen Opiat-(Heroin-)Sucht gleichzusetzen ist. Vorbestehende Suchterkrankungen und andere psychische Störungen sind die wesentlichsten Risikofaktoren. Weitere Nebenwirkungen sind zu beachten. Schmerztherapie bei Suchtkranken stellt eine besondere Herausforderung dar. Schlussfolgerungen: Die Anwendung von OA bei CNTS verlangt eine sorgfältige Indikationsstellung. Die besondere Form der Abhängigkeit von OA ist nicht ausreichend erforscht und wird zu wenig beachtet.

Sign in / Sign up

Export Citation Format

Share Document